ALDH1A1 and neoplasm: SHH002-hu1 significantly enhances the capacity of Bevacizumab to inhibit MDA-MB-231/MDA-MB-468 tumor growth, and reduces the percent of ALDH1+ TNBC cells increased by Bevacizumab